Archived Webinar: ART Options and Treatment Decisions for Women of Reproductive Potential

Assessment of Needs

The webinar will go over the current options for antiretroviral regimens in women of reproductive potential and during pregnancy, with particular attention to pharmacokinetic changes and safety. Further, the presentation will go over recent data on neural tube defects with dolutegravir use in early pregnancy and the resultant changes in WHO guidelines for ART during pregnancy. Finally, the presentation will explore ways in which ART should be further studied in women throughout their lifespan, including during pregnancy and reproductive years.

Learning Objectives

On completion of this webinar, learners will be able to:

• Describe the recent data linking dolutegravir to possible neural tube defects
• Describe the recent guidelines (in high-income and low-income settings) for ART options in women of reproductive potential and pregnant women
• Understand ways in which the pharmacokinetics and safety profile of ART agents during pregnancy can be explored
• Provide practical tips for treating women with HIV during pregnancy or of reproductive potential
• Learn about new initiatives on including pregnant women in clinical trials of new medications

Registration

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Faculty

Dr Gandhi has no relevant financial affiliations to disclose. (Updated 03/12/19)

Peer Reviewer

Dr Abrams has no relevant financial affiliations to disclose. (Updated 03/25/19)

CME Panner and Reviewer

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 03/25/19)